MET and hepatocellular carcinoma: MET fusions have been identified in pan-solid tumors but are rarely observed in other tumors, except for hepatocellular carcinoma (~4%) and glioma (~12%).18,19 Several case reports have suggested that MET TKIs benefit patients with lung cancer, hepatocellular carcinoma, glioma and other refractory tumors with MET fusion.4,5,20,21 However, information on the molecular mechanisms and drug susceptibility of the MET fusion in vitro and in vivo is lacking.